Overview
The CPTAC Uterine Corpus Endometrial Carcinoma (UCEC) Discovery Study is a comprehensive proteogenomic project by the National Cancer Institute (NCI) that analyzed 138 tumors and 20 normal tissues. It provides deep multi-omics data (proteome, acetylome, RNA-seq) to identify druggable pathways, molecular subtypes, and novel biomarkers for improved endometrial cancer diagnosis and treatment.
Key Findings and Data Highlights:
- Study Scope: The CPTAC-UCEC dataset focuses on comprehensive molecular characterization, including over 99-138 cases, often utilized with 543 TCGA samples.
- Proteogenomic Insights: The study identified that PIK3R1 in-frame indels relate to increased AKT phosphorylation (sensitivity to AKT inhibitors) and that CTNNB1 mutations affect Wnt-FZD signaling.
- Biomarker Discoveries: Key findings include potential treatments based on high MYC activity and metformin usage, alongside identifying targets like GINS4 and ESR1 for prognosis. Data Availability: Data is available via the Proteomic Data Commons (PDC) and imaging data is accessible through The Cancer Imaging Archive (TCIA).
- Validation: Findings from this study have been used to validate potential biomarkers such as CDKN2A and to train deep learning models on histopathology images.
The study's data is widely used in bioinformatics to better understand UCEC molecular mechanisms and to aid in clinical stratification.